Encoded raises $280M Series F to push Dravet gene therapy toward registration
What's the deal? Encoded Therapeutics, a clinical-stage biotech developing precision genetic medicines for neurological disorders, has raised a $275 million Series F. GV co-led the round, joined by ARCH Venture Partners, Braidwell LPDealroom has a profile for this one. Try Dealroom →, Farallon Capital ManagementDealroom has a profile for this one. Try Dealroom →, Illumina VenturesDealroom has a profile for this one. Try Dealroom →, InvusDealroom has a profile for this one. Try Dealroom →, Janus Henderson Investors, Matrix Capital ManagementDealroom has a profile for this one. Try Dealroom →, Nolan CapitalDealroom has a profile for this one. Try Dealroom →, RTW InvestmentsDealroom has a profile for this one. Try Dealroom →, SoftBank Vision Fund 2, and Venrock.
Where the money goes: The proceeds will fund the pivotal study of ETX101 in infants and young children with SCN1A+ Dravet syndrome, plus an expansion study in patients up to 18. Funds will also scale up internal GMP manufacturing and advance ETX301 toward a 2027 Investigational New Drug (IND) submission for post-amputation neuroma pain.
Why now? The raise follows interim Phase 1/2 POLARIS data, shared at the European Epilepsy Congress, that Encoded says showed "substantial and sustained seizure frequency reductions alongside encouraging developmental gains." Chief executive officer Kartik Ramamoorthi said the results strengthen the company's conviction in ETX101 and "the potential of our approach to meaningfully alter the course of Dravet syndrome."
What's the endgame? Encoded builds one-time genetic medicines using a vector engineering platform that targets specific cell types in the brain and nervous system. The financing is meant to carry ETX101 through pivotal development toward registration while widening the pipeline.
Investor view: "The emerging clinical profile of ETX101 is increasingly compelling with durable seizure control and promising neurodevelopmental signals," said Brendan Bulik-Sullivan, general partner at GV. Colleague David Schenkein added that Encoded is "well positioned to build a significant portfolio of medicines across neurological diseases."
The signal: At $275 million, this ranks among the largest US health-sector Series F rounds on record — above the 95th percentile in a sample of 146 comparable deals. That scale of late-stage backing signals investor appetite for gene therapies moving from early trials toward the clinic.
Image credit: Encoded Therapeutics, Inc.
